“We are going to Appraise how the commercialization of the substance suits in with our company product at Adastra in an effort to position ourselves to guidance the desire for a secure provide of copyright,” claimed Main executive officer Michael Forbes in the information release. The organization instructed VICE News it wouldn't be commenting